Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Lipid metabolism parameters in patients with Alzheimer disease and their first degree relatives

100%
Czyzewski K., Lalowski M. M., Pfeffer A., Barcikowska M.
Acta Neurobiologiae Experimentalis
|
2001
|
vol. 61
|
issue 1
21-26
EN
Recently, it was suggested that the presence of total cholesterol (TC), age and sex interaction in Alzheimers type dementia (AD) is linked with the apolipoprotein E (APOE) genotype. Our objective was to determine whether the serum lipid profile in AD patients and their first degree non-demented relatives of a certain age (NDR) was dependent on APOE genotype. We included 28 mild to moderate AD and 30 NDR according to DSM-III-R and NINCDS-ADRDA criteria. NDR individuals were investigated in an age group similar to the AD group (brother-sister relationship) and in a group including younger individuals (AD patients-children relationship). Our data indicate significant differences between decreased total cholesterol and low density lipoprotein cholesterol ratio in the group of AD patients versus NDR individuals of similar age, independent of APOE genotype, and an increased total cholesterol and low density lipoprotein cholesterol ratio in a group of AD patients versus their children of the same genotype. There was no significant correlation between triglycerides and high density lipoprotein levels with APOE genotype in any of the tested groups. In conclusion, there was a decreased selected lipid serum profile parameters in AD compared to age matched non demented first degree relatives.
2

Thalidomide increases in vitro sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and cytarabine

100%
Czyzewski K., Zaborowska A., Styczynski J.
Archivum Immunologiae et Therapiae Experimentalis
|
2006
|
vol. 54
|
issue 5
341-345
EN
Introduction: Thalidomide is a derivative of glutamic acid with anti-angiogenic, anti-inflammatory, immunomodulatory and anti-cancer properties that was found to inhibit the production of tumor necrosis factor in vitro, stimulate reactive oxygen species production, and inhibit vascular endothelial growth factor receptor in acute leukemias. The purpose of this study was to determine the in vitro activity of thalidomide as a single agent and in combination with prednisolone or cytarabine in childhood acute lymphoblastic leukemia (ALL). Materials and Methods: Bone marrow samples of 40 childhood ALL patients, normal lymphocytes of 9 healthy adults, and 3 lymphoid cell lines were evaluated for cytotoxicity of thalidomide (alone and in combination with prednisolone and cytarabine) using the MTT assay. Cell cycle analysis was performed by flow cytometry. Results: Thalidomide as a single agent had weak antileukemic activity to the childhood ALL samples. However, in the presence of thalidomide the cytotoxicities of prednisolone and cytarabine were increased 3.3-fold (p<0.001) and 2.7-fold (p=0.002), respectively. Thalidomide increased apoptosis in lymphoblasts and modulated the cell-cycle arrest caused by prednisolone, but not that by cytarabine, in childhood ALL samples. Conclusions: Thalidomide increases in vitro the sensitivity of childhood ALL cells to prednisolone and cytarabine.
3
Content available remote

ApoE polymorphism in Polish patients with Alzheimer's disease

88%
Lalowski M., Czyzewski K., Pfeffer A., Barcikowska M., Kwiecinski H. l.
Acta Neurobiologiae Experimentalis
|
1998
|
vol. 58
|
issue 1
65-68
EN
Alzheimer's disease is a genetically heterogeneous disorder of CNS. The presence of APOE-epsilon4 allele is known to increase the risk of early and late onset sporadic and late onset familial forms of AD. In various Western European countries, USA, Canada, Japan and Australia the allelic frequency ranges between 0.1- 0.18 in controls, and between 0.24- 0.52 in AD patients. In the present study on Polish population, we analyzed the frequency of APOE-epsilon4 allele in persons with Alzheimer's disease (AD). APOE genotypes were determined in 30 mild to moderate AD (83%) and mixed dementia (MIX, 17%), as well as in 11 nondemented first- degree relatives of AD (NDR), recruited from AD patient registry in Warsaw. Among the AD and MIX patients the APOEepsilon4, epsilon3,epsilon2 allele frequency was 0.333, 0.65 and 0.017 respectively.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.